BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Beyond the Basics – Lower-Risk Myelodysplastic Syndromes

Future Perspective on Anemia Treatment in LR-MDS

Video content above is prompted by the following:

What do you see as the future anemia treatment landscape for LR-MDS? What is the impact of newer therapies on the use of ESAs?

What are the current unmet needs in the treatment of anemia in LR-MDS? 

What clinical pearls could you share to community oncologists in the treatment of anemia for patients with LR-MDS?

Videos

Saeed Sadeghi, MD, discusses a case of lower-risk myelodysplastic syndromes (LR-MDS), focusing on the mechanisms of action for luspatercept vs epoetin alfa, insights from the COMMANDS study, real-world data on treatment outcomes, health care resource utilization, and future directions in anemia management within this patient population.

Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these differences may correlate with clinical benefits for patients with lower-risk myelodysplastic syndromes (LR-MDS).

Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of outcome data comparing luspatercept to epoetin alfa in first-line (1L) treatment for lower-risk myelodysplastic syndromes (LR-MDS).

COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

Saeed Sadeghi, MD, reviews real-world data on luspatercept, discussing treatment patterns and outcomes, including transfusion burden, hemoglobin increase, and other key baseline data that may differ from registrational studies in the context of managing lower-risk myelodysplastic syndromes (LR-MDS).

Real-World Data on Luspatercept in LR-MDS

Saeed Sadeghi, MD, discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with myelodysplastic syndromes (MDS), highlighting real-world data presented at SOHO that compares the resource utilization of U.S. patients treated with luspatercept versus erythropoiesis-stimulating agents (ESAs).

Health Care Resource Utilization: Luspatercept vs ESAs in MDS

Saeed Sadeghi, MD, shares his current approach to treating anemia in lower-risk myelodysplastic syndromes (LR-MDS), detailing when to choose erythropoiesis-stimulating agents (ESAs) for first-line treatment, conditions for switching therapies, and factors influencing the decision to use luspatercept as a first-line option, including considerations for dose escalation.

Current Approach to Treating Anemia in LR-MDS

Saeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes (LR-MDS), discussing the impact of emerging therapies on erythropoietin-stimulating agents (ESAs), identifying unmet needs in anemia management, and sharing clinical insights for community oncologists.

Future Perspective on Anemia Treatment in LR-MDS

EP: 1.Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

EP: 2.COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

EP: 3.Real-World Data on Luspatercept in LR-MDS

EP: 4.Health Care Resource Utilization: Luspatercept vs ESAs in MDS

EP: 5.Current Approach to Treating Anemia in LR-MDS

EP: 6.Future Perspective on Anemia Treatment in LR-MDS